(24/7 MARKET NEWS) – Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) announced, this morning, that its three products, SON-1010, SON-1210 and SON-1410 will be evaluated in combination with Janssen Pharmaceutical’s, of Johnson & Johnson, cell therapy assets today a collaboration agreement with Janssen Biotech, Inc.
Sonnet opened this morning at $1.38 and is now at $1.43, up $0.27 (+23.28%), on over 1 million shares trade today.
Its 52-week range is $1.10 to 9.59, with the next key inflection points at $1.55 and $1.74.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
